Current Trends in Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC) – Market Drivers and Challenges
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases
There are currently ten actionable genomic alterations (AGAs) that are addressed by targeted therapy agents across multiple lines of therapy. Patients who did not undergo genetic testing or tested negative for AGAs, receive immunotherapy agents depending on their PD-L1 status. Chemotherapy works as salvage therapy for late-line recurrent/relapsed patients.
– Targeted therapy in NSCLC is a highly competitive and differentiated space covering ten different actionable biomarkers.
– Treatment development for EGFR mutations shifts from label expansion and CNS activity to overcoming resistance mechanisms.
– The relatively quiet ALK and ROS1 segments are to be reshaped by Nuvalent’s TKIs with better efficacy and safety.
– Small molecule + anti-PD-1 combo therapy will unlock new first-line opportunity in the KRAS G12C segment.
Scope
This report includes ten actionable biomarkers in NSCLC that are addressed by targeted therapy agents across multiple lines of therapy. Current and future state of these market segments is included in the scope of the report.
Key Highlights
Report deliverables include a PowerPoint report
AstraZeneca
Pfizer
Boehringer Ingelheim
Lilly
Roche
Cullinan Therapeutics Inc
AbbVie AG
Arrivent Biopharma Inc
Hutchmed China Ltd
Daiichi Sankyo Inc
Xcovery Holdings Inc
Nuvalent Inc
Nuvation Bio Inc
Bristol-Myers Squibb AB
Novartis AG
Amgen AB
MSD B.V.
Jiangsu Hengrui Medicine Co Ltd
Merus Pharma Inc
Apollomics Inc
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Non-Small Cell Lung Cancer reports